Drug conjugate comprising quinoline derivatives

A compound having the formula (II):

• wherein:
• Y1 represents —O—, —NH—, —NHCO—, —NHCORa—, —NHCOO—, —NHCOORb—, —(C2-C6)alkenylene-CO—NH—O— or —(C2-C6)alkenylene-CO—NH—O—;
• R2 represents a group:
• —OCH3, —OCH2CH3, —SCH3, —SCH2CH3 or —OCHF2;
• R3 represents a hydrogen atom or a group:
• —CH3, —CN, —F, —Cl or —ORc;
• R4 represents a hydrogen atom or a group:
• —CH3, —CN, —F, —Cl or —ORd;
• Ra represents a group:
• —(C1-C5)alkylene- or —CF2—;
• Rb represents a group:
• —(C1-C5)alkylene- or —CF2—;
• Rc represents a group:
• —(C1-C5)alkyl or —CF3;
• Rd represents a group:
• —(C1-C5)alkyl or —CF3;
• L represents a linking agent (linker);
• RM* is selected from RM and RM′, wherein RM is a reactive functional group that is able to form a covalent bond with a targeting agent moiety, and wherein RM′ is an RM moiety carrying at least one protecting group;
• in the following state:
• base or salts of bases;
• or in the form of a hydrate or a solvate.

An antibody-drug conjugate having the formula (III):

• wherein:
• Y1 represents —O—, —NH—, —NHCO—, —NHCORa—, —NHCOO—, NHCOORb, —(C2-C6)alkenylene-CO—NH—O— or —(C2-C6)alkenylene-CO—NH—O—;
• R2 represents a group:
• —OCH3, —OCH2CH3, —SCH3, —SCH2CH3 or —OCHF2;
• R3 represents a hydrogen atom or a group:
• —CH3, —CN, —F, —Cl or —ORc;
• R4 represents a hydrogen atom or a group:
• —CH3, —CN, —F, —Cl or —ORd;
• Ra represents a group:
• —(C1-C5)alkylene- or —CF2—;
• Rb represents a group:
• —(C1-C5)alkylene- or —CF2—;
• Rc represents a group:
• —(C1-C5)alkyl or —CF3;
• Rd represents a group:
• —(C1-C5)alkyl or —CF3;
• L represents a linking agent (linker);
• AC represents a targeting agent moiety;
• and
• wherein the DAR (drug-to-antibody [targeting agent] ratio) varies between 1 and 8.